Sotorasib is the first targeted therapy for patients with non–small cell lung cancer (NSCLC) whose tumors express a KRAS G12C mutation and who have received at least 1 prior therapy for their disease.
The KRAS G12C mutation occurs in codon 12 and results in the substitution of a glycine with ctsteine.
The KRAS G12C mutation is induced by smoking and is responsible for about 12% of lung adenocarcinomas..
Lumakras trade name.
Phase 1/2 CodeBreaK 100 clinical trial demonstrated the agent’s ability to induce deep and durable responses in the indicated patient population.
In 124 evaluable patients with locally advanced or metastatic disease progressing after an immune checkpoint inhibitor and/or platinum-based chemotherapy, the objective response rate with sotorasib was 36% with 56% of patients maintaining a response longer than 6 months.
Patients achieving complete and partial responses or stable disease–was 81%.
The most common adverse effects: diarrhea, musculoskeletal pain, nausea, fatigue, liver damage and cough.